Euroopa Liit - eesti - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkootikumid luuhaiguste raviks - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Eesti - eesti - Ravimiamet

fresenius medical care nephrologica deutschland gmbh - kaltsiumatsetaat+magneesiumkarbonaat, raske - õhukese polümeerikattega tablett - 435mg+235mg 180tk

Eesti - eesti - Ravimiamet

desitin arzneimittel gmbh - fenütoiin - tablett - 100mg 100tk